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Abstract Inﬂammation plays a prominent role in tumor
growth. Anti-inﬂammatory drugs have therefore been
proposed as anti-cancer therapeutics. In this study, we
determined the anti-angiogenic activity of a single dose of
liposomal prednisolone phosphate (PLP-L), by monitoring
tumor vascular function and viability over a period of one
week. C57BL/6 mice were inoculated subcutaneously with
B16F10 melanoma cells. Six animals were PLP-L-treated
and six served as control. Tumor tissue and vascular
function were probed using MRI before and at three
timepoints after treatment. DCE-MRI was used to deter-
mine K
trans,v e, time-to-peak, initial slope and the fraction
of non-enhancing pixels, complemented with immunohis-
tochemistry. The apparent diffusion coefﬁcient (ADC), T2
and tumor size were assessed with MRI as well. PLP-L
treatment resulted in smaller tumors and caused a signiﬁ-
cant drop in K
trans 48 h post-treatment, which was main-
tained until one week after drug administration. However,
this effect was not sufﬁcient to signiﬁcantly distinguish
treated from non-treated animals. The therapy did not
affect tumor tissue viability but did prevent the ADC
decrease observed in the control group. No evidence for
PLP-L-induced tumor vessel normalization was found on
histology. Treatment with PLP-L altered tumor vascular
function. This effect did not fully explain the tumor growth
inhibition, suggesting a broader spectrum of PLP-L
activities.
Keywords Anti-angiogenic effects   Tumor-associated
inﬂammation   Glucocorticoids   Liposomes   DCE-MRI
Introduction
Inﬂammation is a common feature of the tumor microen-
vironment, which, according to recent ﬁndings, plays a
prominent role in tumor growth propagation [1, 2]. The
close relationship between cancer and inﬂammatory pro-
cesses prompted the idea of silencing tumor-associated
inﬂammation for therapeutic purposes [3]. Consequently,
anti-inﬂammatory drugs, widely used in clinical practice,
have been proposed as potential anti-cancer therapeutics.
One of these agents, celecoxib, has recently entered clinical
trials, promising a valuable contribution of anti-inﬂam-
matory therapy to cancer prevention and treatment [4–7].
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DOI 10.1007/s10456-010-9198-5The anti-tumor activity of glucocorticoids (GC), known
as steroid anti-inﬂammatory agents, has been demonstrated
in mouse tumor models [8, 9]. However, adverse effects
caused by high daily doses, necessary to achieve tumor
growth inhibition, were found to be a major limitation.
Recently, encapsulation into long-circulating liposomes
was demonstrated to be an effective strategy to enhance
intratumoral GC concentration [10] as a result of favorable
pharmacokinetic properties of liposomes [11, 12] and the
enhanced permeability and retention of tumor tissue [13].
Importantly, the employment of the liposomal drug deliv-
ery system dramatically decreased the therapeutic dose and
the dosing frequency compared to that of the free drug. For
prednisolone phosphate (PLP), which was found to have
the most favorable therapeutic index among investigated
liposome-encapsulated GC [14], a single intravenous
injection of 20 mg PLP/kg/week was sufﬁcient to signiﬁ-
cantly inhibit tumor growth in B16F10 melanoma and C26
colon carcinoma [10].
Inhibition of angiogenesis was proposed to be a key
effect of liposomal GC therapy, leading to tumor growth
delay [10]. Findings that support this hypothesis include a
decreased expression of multiple pro-angiogenic factors
[15] and the inhibition of macrophage activity in the tumor
[16], both of which play an important role in the process of
neovascularisation. In addition, anti-proliferative effects of
liposomal GC on endothelial cells were observed in vitro
[14, 15]. However, the inﬂuence of liposomal GC on the
structure and the function of the tumor vasculature has not
yet been investigated. The evaluation of the tumor vascular
response is essential to fully characterize the anti-angio-
genic activity of liposomal GC and to provide better
understanding of the anti-tumor mechanism.
In the present study, we therefore aimed to determine
the anti-angiogenic potency of liposomal prednisolone
phosphate (PLP-L) by studying its effect on the tumor
vasculature. The efﬁciency of a single dose of PLP-L
(20 mg PLP/kg) was investigated in B16F10 murine mel-
anoma during one week. For comprehensive characteriza-
tion of the vascular status, both in vivo magnetic resonance
imaging (MRI) and histological analyses were performed.
In vivo evaluation of the vascular changes induced by
PLP-L was done using dynamic contrast-enhanced MRI
(DCE-MRI). This method enables non-invasive character-
ization of the vessel function, based on the pharmacoki-
netics of a low molecular weight gadolinium chelate [17].
Due to the sensitivity to changes in vascular density and
permeability, DCE-MRI-derived parameters, such as the
endothelial transfer constant K
trans, serve as valuable in
vivo markers of anti-angiogenic effects [18].
Furthermore, we investigated the effect of PLP-L on the
tumor viability, since the expected vascular suppression, by
limiting the availability of oxygen and nutrients to rapidly
multiplying tumor cells, may lead to cell death. For char-
acterization of this tissue property, we used two DCE-MRI-
derived parameters, i.e., the fraction of extravascular
extracellular space (ve) and the fraction of non-enhancing
pixels. Moreover, we assessed the apparent diffusion
coefﬁcient (ADC) and the transverse relaxation time (T2),
which are signiﬁcant complementary MR indicators of
changes in the cellular density and the occurrence of local
hemorrhages [19, 20].
As a ﬁnal step of the vascular response assessment, we
performed immunohistochemical examination of tumor
tissues after the in vivo measurements, at the end of the
study. Two aspects related to the anti-angiogenic activity
of PLP-L were investigated. First, we determined the
microvessel density (MVD), which is the most established
histological marker of the vascular status and response to
anti-angiogenic therapy [21, 22]. Secondly, we investigated
whether PLP-L treatment induced tumor vessel normali-
zation, an effect previously described for anti-angiogenic
agents [23]. As a marker of vessel maturation we consid-
ered the presence of a smooth muscle layer around the
vascular endothelium.
Materials and methods
Preparation and characterization of PLP-L
PLP-L were prepared as described previously [24]. In
short, appropriate amounts of 1,2-dipalmitoyl-sn-glycero-
3-phosphocholine (DPPC), cholesterol, and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[methoxy(polyeth-
ylene glycol)-2000] (PEG2000-DSPE), obtained from
Avanti Polar Lipids (Albaster, AL, USA), were mixed at
1.85/1/0.15 molar ratio. Subsequently, the lipids were
dissolved in chloroform/methanol 1:1 (v/v) and dried by
rotary evaporation. The dry lipid ﬁlm was hydrated in an
aqueous solution of 100 mg/mL of prednisolone phosphate
(PLP) (Fagron, Nieuwerkerk a/d IJssel, The Netherlands).
The resulting multilamellar lipid vesicles were extruded
(Lipofast Extruder, Avestin, Toronto, Canada) 6 times
through polycarbonate membrane ﬁlters with a pore
diameter of 200 and 100 nm (Costar, Cambridge, MA,
USA) at 55C. Non-encapsulated PLP was removed using
dialysis in HEPES buffered saline (pH 7.4) (Sigma–
Aldrich, St. Louis, MO, USA). A dialysis membrane with a
molecular weight cutoff between 12 and 14 kDa (Spectrum
Laboratories Inc., CA, USA) was used. During 24 h of
dialysis the buffer was repeatedly replenished. The ﬁnal
PLP-L preparation was stored at 4C.
The mean diameter and size distribution of the lipo-
somes were determined with dynamic light scattering
(Zetasizer Nano, Malvern, UK) at 25C. The phospholipid
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123content in the liposome suspensions was assessed using
phosphate analysis according to Rouser [25] and the con-
centration of liposome-encapsulated prednisolone phos-
phate was analyzed with high performance liquid
chromatography [15]. A mean diameter of 100 nm and a
narrow size distribution (polydispersity index = 0.1) were
determined for the prepared liposomes. The drug and the
lipid concentrations were 5 mg/mL and 60 lmol/mL,
respectively.
Murine tumor model
B16F10 murine melanoma cells were cultured as a mono-
layer at 37C and 5% CO2, in DMEM medium (1 g glucose/
L) (Invitrogen, Breda, The Netherlands), supplemented
with 10% fetal bovine serum (Greiner Bio-One, Alphen a/d
Rijn, The Netherlands), 2 mmol/L L-glutamine (Lonza
Bioscience, Basel, Switzerland), and 50U/mL penicillin/
streptomycin (Lonza Bioscience). The cell line originates
from American Type Culture Collection (CRL-6475).
Six to eight week-old C57BL/6 mice (Charles River,
Maastricht, The Netherlands) were inoculated with
1 9 10
6 B16F10 cells subcutaneously in the right ﬂank.
Between day 7 and 9 after inoculation, the tumors became
palpable in all mice. The animal experiments were
approved by the Institutional Ethical Review Committee
for animal experiments of Maastricht University (The
Netherlands).
Study design
The timeline of the study is presented in Fig. 1a. The pre-
treatment MRI examination was performed on a day when
tumors became palpable (Day 0). After the pre-treatment
MRI scans were acquired, the animals received a single
dose of either PLP-L (20 mg PLP/kg) (n = 6, PLP-L-
treated group) or a corresponding volume of saline (n = 6,
Control group) intravenously. The post-treatment MRI
examinations were performed on Day 2, Day 4 and Day 6.
The time frame of our study was chosen in view of the one
week-long therapeutic efﬁcacy of PLP-L [10] and the fast
growth of B16F10 tumors. After MRI measurements on
Day 6, the mice were sacriﬁced and the dissected tumors
were immunohistochemically analyzed.
MRI acquisition
MRI measurements were performed with a 6.3T scanner
(Bruker, Biospin, Ettlingen, Germany), using a 3 cm
birdcage coil (Rapid Biomedical, Rimpar, Germany). The
mice were anesthetized with isoﬂurane and placed in a
cradle, equipped with a mask for anesthetic gas and a warm
water pad. An infusion line ﬁlled with contrast agent was
placed in the tail vein to enable injection during the MRI
experiment. Respiration was monitored with a balloon
sensor connected to an ECG/respiratory unit (Rapid Bio-
medical). The imaging protocol included a fat-suppressed
multi-slice T2-weighted spin-echo sequence (TE/TR = 35/
4,200 ms, number of averages (NA) = 4) and a multi-slice
diffusion-weighted spin-echo sequence (TE/TR = 35/
2,000 ms, 3 directions, b-value = 0, 400 s/mm
2,N A= 2).
Quantitative T2 maps were obtained using a multi-echo
method, consisting of a series of T2-weighted spin-echo
images with 16 different TE values varying from 9 to
144 ms (TR = 2,000 ms, NA = 2). T1-weighted dynamic
contrast-enhanced series (RF-spoiled FLASH, TR/
TE = 80/3.0 ms, ﬂip angle = 50, number of slices = 8)
were acquired for a duration of 25 min with NA = 2
(n = 100, sampling time = 15.36 s), or NA = 1( n= 200,
sampling time = 7.68 s). A dose of 0.3 mmol/kg of Gad-
oteridol (Prohance, Bracco Diagnostics, Princeton, NJ,
USA) was manually injected as a bolus in the tail vein 80 s
after the start of acquisition. All acquired images had a
matrix size of 128 9 128, ﬁeld of view of 3 9 3c m
2 and
1 mm slice thickness. The image iso-center and orientation
were the same for all scans.
MRI data analysis
Analysis of T2- and diffusion-weighted images was per-
formed in Mathematica 6.0 (Wolfram Research Inc.,
Champaign, IL, USA). Regions of interest (ROIs) were
manually deﬁned by drawing contours around the tumor
area in every diffusion-weighted image slice in which the
tumor was visible. T2-weighted images served as an
Fig. 1 a Timeline of the study; b tumor growth curves for PLP-L-
treated and saline-treated mice (Control) (mean ± SD, n = 6). ‘‘*’’
indicates signiﬁcant difference in tumor volume between PLP-L-
treated and Control mice on Day 6
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123additional reference. Tumor volumes were calculated by
multiplying the number of pixels in the tumor ROIs with
the pixel volume. ADC maps were generated from ﬁtting
diffusion-weighted imaging data according to the equation
ADC =-1/b ln(S/S0), where S and S0 are signals at
b = 400 and b = 0 s/mm
2, respectively [26]. T2 maps
were calculated in each slice from mono-exponential decay
ﬁtting of the multi-echo data.
DCE-MRI data processing was performed in Matlab
(Mathworks, Natick, MA, USA). The analysis included
those pixels within the tumor ROI that showed signiﬁcant
signal enhancement, i.e., enhancement equal to or greater
than 5 times the noise level. The standard deviation of the
noise was determined in air and corrected for the Rician
distribution [27]. The fraction of non-enhancing pixels in
the total tumor area was quantiﬁed and used as a tissue
viability-related parameter.
The DCE-MRI signal intensity curves were converted to
contrast agent concentration curves (Ct) using a previously
published reference method [28]. The pre-contrast refer-
ence was taken from a user-deﬁned ROI in muscle (5 9 5
voxels). A pre-contrast T1 value of 1,285 ms for muscle
[29] and a relaxivity value of 3.7 mM
-1 s
-1 for Gadoter-
idol (measured at 6.3T at 20C) were used in the
calculations.
The Ct curves in the selected pixels of the tumor ROI
were analyzed. First, by applying the basic two-compart-
ment model by Tofts et al. [30]:
dCt=dt = KtransðCp Ct=veÞ;
where ve is the fraction of extravascular extracellular space
(EES), K
trans (min
-1) is the volume transfer constant
between blood plasma and EES, Cp (mM) is the contrast
agent concentration in the blood plasma space, and Ct
(mM) is the contrast agent concentration in the tissue of
interest. The input function Cp was derived from the con-
trast agent uptake in skeletal muscle using the reference
tissue approach [31, 32], assuming literature values for
K
trans (0.11 min
-1) and ve (0.20) [31]. To minimize noise
propagation, the muscle curve was ﬁtted with an empirical
mathematical model [33] prior to this derivation. We used
the ﬁrst 5 min of the DCE-MRI scan [33]. The ﬁtting was
performed with a golden section search method, by mini-
mizing the goodness-of-ﬁt measure R
2 [34]. In addition to
the applied enhancement threshold (enhancement C 5
times the noise level), we excluded erroneous ﬁts by dis-
carding pixels with a ve value equal to or greater than 0.95.
Secondly, the descriptive parameters time-to-peak
(Tpeak) and initial slope (Slopei) were derived from the Ct
curves [35]. Tpeak (min) is the time elapsed between the
start of enhancement and the timepoint at which the con-
trast agent reached its maximal concentration (Ct,peak).
Slopei (mM/min) approximates the upslope of Ct:
Slopei ¼ Ct;peak=Tpeak:
For consistency, also here only data acquired in the ﬁrst
5 min was taken into account.
Immunohistochemical analysis of tumor tissues
Tumors were snap-frozen in isopentane and stored at
-80C. Five lm-thick sections were cut and ﬁxed with ice-
cold acetone for 5 min. In order to assess the microvessel
density (MVD), endothelial cells were stained with rat anti-
mouse CD31 primary antibody (BioLegend, San Diego,
CA, USA). FITC-conjugated rabbit anti-rat IgG (Dako,
Glostrup, Denmark) was used as a secondary antibody. For
nuclear staining, 4,6’-diamidino-2-phenylindole (DAPI)
(Molecular Probes, Eugene, Oregon, USA) was applied.
The tissue samples were examined with a ﬂuorescence
microscope (Zeiss, Sliedrecht, The Netherlands). MVD
was assessed according to the method described by We-
idner et al. [21], by counting the number of vessels in ﬁve
vascular regions of a section at 2009 magniﬁcation. To
investigate vessel normalization, another set of tissue sec-
tions was stained with monoclonal anti-actin, a-smooth
muscle-FITC antibody (Sigma–Aldrich). Co-staining was
done with rat anti-mouse CD31 antibody (BioLegend) and
Alexa Fluor 350-conjugated goat anti-rat IgG (Molecular
Probes). The presence of normalized vessels was examined
using ﬂuorescence microscope (Zeiss).
Statistical analysis
All data are reported as mean ± standard deviation (SD).
Statistical analysis was performed in SPSS 16.0 (SPSS Inc.,
Chicago, Illinois, USA). A t test was used to assess the
difference between tumor volumes of PLP-L-treated and
Control mice at different study timepoints. Statistical
analysis of DCE-MRI data was performed on median, 25,
75, 95th percentile values and interquartile range (distance
between 25 and 75th percentile values), determined from
histograms of K
trans,v e,T peak and Slopei for each data set
[36]. The comparison between the results obtained at dif-
ferent timepoints after drug or saline administration and the
baseline readout was done using a paired t test. The com-
parison of the longitudinal data obtained for both treated
and control animals was done using mixed-factors
ANOVA for repeated measures, where the within-subject
factor was time and the between-subject factor was treat-
ment. For this analysis, we used the relative change in the
parameter with respect to its baseline value. The fraction of
non-enhancing pixels, ADC and T2 data were tested using
the same statistical methods as described above for the
DCE-MRI-derived kinetic parameters. For ADC and T2,
the median was used as comparison parameter. The
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123analysis of the MVD data was done using a t test. In all
analyses, the difference was considered signiﬁcant at
P\0.05.
Results
Effects of PLP-L on tumor growth
To evaluate the effect of PLP-L on tumor growth we
monitored lesion size over time, using high resolution MRI
measurements. Tumor growth curves, which represent
summarized data obtained for the PLP-L-treated and the
Control group, are presented in Fig. 1b. During the ﬁrst
days after PLP-L administration (Day 2 and 4), tumor
volumes were not signiﬁcantly affected by the treatment.
The growth-inhibiting effect of PLP-L became evident on
Day 6, which corresponds to the previous ﬁndings [10, 14].
At this timepoint, tumors of PLP-L-treated mice were on
average a factor of two smaller than those of the Control
group.
Evaluation of anti-angiogenic effects of PLP-L
with DCE-MRI
As markers of vascular function, we used K
trans,T peak and
Slopei, estimated by mathematical modeling of dynamic
contrast-enhanced MRI scans. Because ve is a measure of
cellular density rather than vessel function, it is discussed
in the next section. All assessed parameters are
summarized in Table S1 (supplementary material), whereas
representative MR images and K
trans maps obtained for
PLP-L and Control mice are presented in Fig. 2.
Large variability in DCE-MRI parameters was observed
already in the pre-treatment measurements (Fig. 3, Table
S1), indicating natural inter-tumor differences in vascular
function. Therefore, we used baseline measurements as a
reference for the assessment of vascular effects. In all PLP-
L-treated tumors, the ﬁrst post-treatment examination
revealed a reduction in median K
trans by 27 ± 14% com-
pared to the pre-treatment state (Fig. 3a). This signiﬁcant
drop in this parameter was maintained on Day 4 and 6,
resulting, on average, in 40 and 45% decreased median
K
trans, respectively, as compared to pre-treatment values.
The same trend was observed for the 25 and 75th K
trans
percentiles (Table S1). For the 95th percentile, which
reﬂects the fraction of K
trans ‘‘hot spots’’ often associated
with intensive tumor growth [37], no change was found at
any timepoint (Table S1). Interestingly, for the therapy
group the interquartile range was signiﬁcantly decreased on
Day 2 (25 ± 15%) and 4 (33 ± 25%), which indicates a
more narrow distribution of K
trans values throughout the
enhancing tumor area (Table S1). Moreover, Tpeak was
clearly affected by the therapy; after an initial increase of
60% on Day 2, it was maintained at approximately the
same level (Fig. 3c). A signiﬁcant therapy-induced drop in
Slopei was observed only on Day 6. In contrast, in the
Control group, no signiﬁcant change in any of the DCE-
MRI parameters was observed, neither on Day 2 nor Day 4
(Fig. 3, Table S1). Surprisingly, on the last measurement
day (Day 6) a decrease in median K
trans (40 ± 18%) and
Fig. 2 Representative
diffusion-weighted images
(DWI), T1-weighted images
(T1w) 60 s after start of
enhancement and corresponding
K
trans maps obtained for a
PLP-L-treated and a control
mouse before (Day 0) and at
different timepoints after PLP-L
or saline (Control)
administration
(Day 2, 4, 6)
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123median Slopei (48 ± 18%) became apparent in the Control
group (Fig. 3a,d), taking the Day 0 data as a reference.
To test, whether the assessed kinetic parameters could
serve as non-invasive imaging markers of the therapeutic
response, we performed a statistical comparison between
the longitudinal data obtained for the PLP-L-treated and
the Control group. The analysis revealed no signiﬁcant
inﬂuence of the PLP-L treatment on DCE-MRI-based
markers compared to the Control. This result refers to all
assessed parameters, indicating that, under the present
experimental conditions, DCE-MRI failed to distinguish
the response to PLP-L treatment from the normal tumor
development.
Evaluation of the tumor viability
The effect of PLP-L treatment on the tumor tissue viability
was characterized by means of four MR parameters, ve, the
fraction of non-enhancing pixels, ADC and T2. Both DCE-
MRI-derived markers, i.e., ve and the fraction of non-
enhancing pixels, did not change signiﬁcantly after
administration of PLP-L (Fig. 3b, Table S1). Similarly, in
the Control group they remained stable over time. The
results of ADC and T2 measurements are summarized in
Fig. 4. Neither ADC nor T2 were signiﬁcantly affected by
the treatment with PLP-L. The constant median values of
ADC and T2 of approximately 0.83 9 10
-3 mm
2/s and
62 ms, respectively, throughout the investigation suggest
that the therapy did not cause necrotic changes in the
tumor. Interestingly, for the Control group we observed a
decrease in median ADC over time (Fig. 4a). A signiﬁcant
drop compared to the starting point was noted already on
Day 2. The trend of decreasing ADC observed throughout
the experiment suggests that the normal tumor growth is
accompanied by an increase in cellular density. On the
other hand, T2 remained relatively stable (Fig. 4b). For
Fig. 3 Inﬂuence of PLP-L
treatment on median a K
trans,
b ve, c Tpeak and d Slopei in the
tumor, compared to the Control
(mean ± SD, n = 6). Symbols
‘‘*, #’’ indicate signiﬁcant
difference compared to baseline
(Day 0) for PLP-L (*) and
Control group (#) (P\0.05)
Fig. 4 Effect of PLP-L on
median (a) apparent diffusion
coefﬁcient (ADC) and
b transverse relaxation time (T2)
in the tumor, compared to the
Control (mean ± SD, n = 6).
Symbol ‘‘*’’ indicates
signiﬁcantly decreased median
ADC values compared to
baseline measurements reported
for the Control
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niﬁcant inﬂuence of the PLP-L treatment compared to the
Control.
Microvessel density and vessel normalization
Ex vivo analysis of tumor tissues was performed after MRI
experiments, thus, one week after administration of PLP-L
or saline. First, we assessed the microvessel density
(MVD), which is an important marker of the tumor
angiogenic activity. The summarized results of this anal-
ysis are presented in Fig. 5. The average MVD of 34
vessels/mm
2 assessed in PLP-L-treated tumors was lower
compared to 58 vessels/mm
2 in the Control group. Nev-
ertheless, statistical analysis did not conﬁrm a signiﬁcant
difference in MVD. In addition, we investigated the rela-
tion between MVD and K
trans, being important ex vivo and
in vivo markers of the vascular status, respectively. How-
ever, we did not ﬁnd a correlation between these two
parameters (r
2 = 0.23).
To investigate vascular maturation, which was consid-
ered as a potential effect of PLP-L, the tumor sections were
examined for the presence of the smooth muscle layer
around the endothelium of tumor vessels. Both PLP-L-
treated and Control tumor sections were analyzed and
compared to normal muscle tissue, which was used as a
reference. In Fig. 6a, a normal vessel of the muscle is
presented. It is characterized by a continuous rim of
smooth muscle cells around the endothelium. We did not
observe such well-formed vessels in both PLP-L-treated
and Control tumors (Fig. 6b,c). Predominantly, tumor
vessel walls were composed of a bare endothelial cell
layer. If smooth muscle staining was present in the tumor
tissue, it appeared to be disturbed and poorly deﬁned
(Fig. 6c). This observation refers to both the PLP-L-treated
and the Control group, which suggests that this is not a
therapy-induced effect.
Discussion
In the current study, we evaluated the response of tumor
vasculature to PLP-L treatment using in vivo MRI and
immunohistochemical analyses. DCE-MRI monitoring
revealed therapy-induced vascular alterations that were
manifested by a signiﬁcant decrease in K
trans and con-
comitant increase in Tpeak. At the same time, the treatment
did not inﬂuence any of the MR parameters related to the
tumor tissue viability. Interestingly, PLP-L administration
prevented the drop in ADC values over time that was
observed in non-treated tumors. Surprisingly, the tumor
growth in the Control group was also accompanied by a
signiﬁcant decrease in K
trans and Slopei one week after start
of the experiment. Moreover, at this timepoint, neither a
statistically important difference in MVD between the
PLP-L-treated and the Control group, nor signs of therapy-
induced tumor vessel normalization were found. The cur-
rent ﬁndings provide a rather complex picture of the vas-
cular effects of PLP-L. On one hand, the DCE-MRI results
support the thesis on angiogenesis inhibition underlying
Fig. 5 a Representative
ﬂuorescence microscopy images
of tumor sections from Control
and PLP-L-treated mice. CD31-
stained endothelial cells are
shown in green and cell nuclei
in blue (DAPI). b Microvessel
density (MVD) assessed for
Control (white bar) and PLP-L-
treated (grey bar) tumors. Bars
represent mean ± SD (n = 6)
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123tumor growth suppression by PLP-L. However, we did not
ﬁnd a signiﬁcant difference in vascular parameters between
PLP-L-treated and Control tumors, which we attribute to
high inter-tumor variability and vascular alterations that
accompany normal tumor development.
Glucocorticoids (GC) are among the most effective
anti-inﬂammatory and immunosuppressive agents [38]. In
clinical oncology, they are included in all therapeutic
regimes of lymphatic tissue malignancies [39]. Moreover,
they are used as a part of endocrine therapy in breast and
prostate cancer, and as anti-edema agents in brain tumors
[39, 40]. GC are also widely applied in prevention and
treatment of chemotherapy-associated side effects, such
as nausea and allergic reactions. However, the inﬂuence
of GC on the growth of solid tumors is a topic of
ongoing scientiﬁc debate. This is due to the unclear role
of the glucocorticoid receptor in the regulation of
malignant cells and the still controversial idea of anti-
immune therapy as anti-cancer strategy [39, 40]. Never-
theless, the broad spectrum of GC activities, including
anti-inﬂammatory, anti-angiogenic, anti-edema, necrotic
and apoptotic actions, appears to be very attractive for
the treatment of such a complex disease as cancer. In
support of this, several pre-clinical investigations dem-
onstrated the therapeutic efﬁcacy of GC in animal tumor
models [8, 9]. In contrast, other pre-clinical and, to some
extent, clinical data suggest that GC induce resistance to
chemo- and radio-therapy and increase metastatic
potential [40].
In this study, we conﬁrmed the previously reported
inhibitory effect of PLP-L on the growth of B16F10 mel-
anoma. The mechanism underlying this effect may involve
the complex interaction of the drug with the tumor
microenvironment. Therefore, versatile techniques, such as
MRI, which provide extensive morphological and func-
tional information, are especially attractive for therapy
evaluation. Moreover, the application of non-invasive
methods facilitates translation from the preclinical to the
clinical setting. MR measurements of water diffusion and
vessel function were previously employed to study the
effects of GC therapy in brain tumors. Several patient
studies demonstrated a signiﬁcantly reduced mean diffu-
sivity in peritumoral edematous brain and ADC in the
tumor after dexamethasone treatment [41, 42]. Moreover,
GC were found to decrease blood-tumor barrier perme-
ability. Armitage et al. [43] integrated diffusion, perfusion
and permeability MRI to characterize the response of
intracranial tumors to dexamethasone. Signiﬁcantly
reduced K
trans,v e, and vp (the fractional plasma volume)
were observed 48–72 h after treatment in glioblastoma,
however, not in meningioma and metastatic carcinoma.
Furthermore, Crokart et al. [44] performed DCE-MRI
using the rapid-clearance blood pool agent P792 (Vista-
rem) to assess tumor perfusion and permeability 30 min
after hydrocortisone administration. The fraction of per-
fused pixels of 37.7 ± 10.8% in treated tumors was found
to be signiﬁcantly lower than in Control tumors. However,
neither K
trans,v p nor the redistribution rate constant kep
Fig. 6 Representative
ﬂuorescence microscopy images
of the tumor and surrounding
muscle tissue. Anti-a-SMA
staining of smooth muscle cells
is shown in green and CD31
staining of endothelial cells in
blue. a An example of a mature
vessel in skeletal muscle,
showing a ring of smooth
muscle cells around
endothelium. b The border
region between the tumor and
the normal muscle tissue,
containing anti-a-SMA-negative
vessels (tumor) and multiple
vessels with pronounced anti-a-
SMA staining (indicated with
white arrows in muscle tissue).
c Tumor vasculature, among
which a single vessel was found
to have a discontinuous smooth
muscle layer (indicated with
white arrow and shown in a
higher magniﬁcation in the
inset)
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123were affected. All the aforementioned studies have shown
the potential of MRI for detection of the anti-tumor effects
of steroid anti-inﬂammatory agents.
To monitor the response of tumor vasculature to ther-
apy with PLP-L, we used DCE-MRI, which is currently
the leading in vivo method for the assessment of anti-
angiogenic effects [18, 45]. Generally, we observed a
large variability between individuals, starting already at
the pre-treatment state. By using baseline measurements
as a reference, we found signiﬁcantly reduced median
K
trans after the PLP-L treatment. Moreover, a decreased
interquartile range of K
trans distribution on Day 2 and 4
indicated a more homogenous tumor vascular function in
PLP-L-treated mice. The suppressive effect on tumor
vasculature was further supported by signiﬁcantly
increased Tpeak. However, when the summarized data of
the PLP-L-treated and the Control mice were compared,
no clear anti-angiogenic effect of PLP-L was detected.
We believe that this is due to the aforementioned inter-
tumor variability of vessel function, observed throughout
the course of the experiment. Moreover, we found that
non-treated tumors followed eventually the same trend of
changes in vascular parameters as PLP-treated lesions.
This occurred later in time, on Day 6, indicating tumor
growth-dependent factors as a source of the decreased
vascular function in the Control group. We avoided the
interference of necrotic regions with these results, as non-
enhancing pixels were excluded from DCE-MRI analysis.
However, another important tumor tissue property, the
interstitial ﬂuid pressure, which is known to increase with
tumor growth [46], could have played a role in the
observed effect. Interestingly, on Day 6, we also did not
ﬁnd a signiﬁcant difference in MVD between the PLP-L-
treated and the Control group. At the same time, MVD
did not correlate with median K
trans assessed on Day 6.
The dissociation between MRI-based and histopatholo-
gical parameters can be explained by the different char-
acter of these measures [37]. Despite that, both DCE-MRI
and histological readout led to the same conclusion that
PLP-L did not affect the vasculature signiﬁcantly com-
pared to the Control.
The extraction of separate estimates of blood ﬂow and
vascular permeability, as well as vascular fraction (vp), by
using more complex pharmacokinetics modeling, might
provide additional insights into the vascular effects of PLP-
L[ 47]. In the present study, we applied the basic Tofts
model, which does not incorporate the vascular fraction
(vp) as a model parameter. This was motivated by too low
temporal resolution of the T1-weighted dynamic scan.
According to Henderson et al. [48], reliable vp assessment
requires a temporal resolution of at least 4 s for human
data. Separate estimates of ﬂow and permeability instead of
K
trans require even higher temporal resolution [49].
As supportive parameters we used those related to the
tumor tissue viability, i.e., ve, the fraction of non-enhanc-
ing pixels, ADC and T2. We found that the PLP-L treat-
ment did not result in signiﬁcant changes in either of the
aforementioned parameters, indicating undisturbed tumor-
cell density and stable necrotic fraction. Interestingly, we
reported a consistent decay of the tumor ADC over time in
the Control group. Since this was not observed after PLP-L
administration, we can conclude that the treatment does not
only affect the tumor size but also prevents an increase of
tumor-cell density.
An important point of our investigation was to deter-
mine, whether angiogenesis-related parameters are suitable
markers of the therapeutic efﬁcacy of PLP-L. Previous
studies on the anti-angiogenic effects of PLP-L were
focused predominantly on molecular markers of angio-
genesis. Banciu et al. [15] reported a signiﬁcantly reduced
expression of the basic ﬁbroblast growth factor and a wide
range of inﬂammatory mediators involved in the process of
angiogenesis. At the same time, the vascular endothelial
growth factor was not affected by the treatment. We
hypothesized that the diagnostic criteria used for angio-
genesis inhibitors can be also applied for PLP-L. However,
we found that neither MR nor histopathological vascular
markers were capable of differentiating between the PLP-
L-treated and the Control tumors. This was surprising,
since the PLP-L treatment resulted in an over 40% decrease
in median K
trans, which is often considered a true positive
response to the anti-angiogenic treatment [18]. However,
this was also observed for the Control group on Day 6.
Therefore, the assessed vascular parameters appear to be of
limited value as biomarkers of the response to liposomal
GC. Ideally, the biological endpoint should relate speciﬁ-
cally to the mechanism of the therapeutic action. However,
due to a broad spectrum of GC activities, the identiﬁcation
of a speciﬁc therapeutic marker might be very challenging.
Considering the previous ﬁndings [15, 16], the most
promising markers appear to be those related to the
silencing effects of GC on the tumor-associated inﬂam-
mation. The non-invasive assessment of this type of
information requires the use of cellular and molecular
imaging techniques.
In conclusion, we provided evidence that treatment with
PLP-L suppresses the functioning of tumor vasculature,
which can subsequently lead to tumor growth inhibition.
The anti-angiogenic effects of PLP-L were manifested by a
signiﬁcant drop in tumor K
trans 48 h post-treatment, which
was maintained until one week after drug administration.
However, we also observed naturally occurring vascular
alterations in the Control group. The obtained results
suggest that angiogenesis monitoring does not provide
sufﬁcient information on the therapeutic efﬁcacy of PLP-L.
Therefore, more speciﬁc markers of the anti-tumor activity
Angiogenesis (2011) 14:143–153 151
123of liposomal glucocorticoids are desired. Among the
potential candidates are those directly related to the sup-
pression of inﬂammatory processes in the tumor.
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